Tetraidothyroacetic acid (Tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3825-3831

  Yalcin, M ^a,b   Bharali, D J ^a   Lansing, L ^a   Dyskin, E ^a   Mousa, S S ^a   Hercbergs, A ^e   Davis, F B ^c   Davis, P J ^c,d,e   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ULUDAG UNIVERSITY   (Turkey)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Anti angiogenesis; Anti cancer; Integrin; Renal cell carcinoma; Tetrac; Tetrac nanoparticles

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL SURFACE RECEPTOR; HEMOGLOBIN; INTEGRIN RECEPTOR; LEVOTHYROXINE; LIOTHYRONINE; MATRIGEL; NANOPARTICLE; POLYGLACTIN; TETRAIODOTHYROACETIC ACID; TETRAIODOTHYROACETIC ACID POLYGLACTIN CONJUGATE; THYROID HORMONE RECEPTOR; THYROXINE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CELL PROLIFERATION; CELL TYPE; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DRUG EFFECT; DRUG STRUCTURE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULAR SMOOTH MUSCLE; WEIGHT GAIN;

ANIMALS; CARCINOMA, RENAL CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; HUMANS; KIDNEY NEOPLASMS; LACTIC ACID; MICE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; POLYGLYCOLIC ACID; THYROXINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71949098379     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pascual D and Borque A: Epidemiology of kidney cancer. Adv Urol 782381, 2008.
2. Decastro GJ and McKiernan JM: Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 35(4): 581-592, 2008.
3. Mohammed A, Shergill I and Little B: Management of metastatic renal cell carcinoma: current trends. Expert Rev Mol Diagn 9(1): 75-83, 2009.
4. Heng DY and Bukowski RM: Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets 8(8): 676-682, 2008.
5. Bergh JJ, Lin HY, Lansing L et al: Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146: 2864-2871, 2005. (Pubitemid 41002793)
6. Davis FB, Mousa SA, O'Connor L et al: Proangiogenic action of thyroid hormone is fibroblast growth factor dependent and is initiated at the cell surface. Circ Res 94: 1500-1506, 2004. (Pubitemid 38780323)
7. Mousa SA, O'Connor L, Davis FB et al: Proangiogenesis action of the thyroid hormone analog 3, 5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147: 1602-1607, 2006.
8. Davis FB, Tang HY, Shih A, Keating T et al: Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 66: 7270-7275, 2006. (Pubitemid 44197708)
9. Lin HY, Tang HY, Shih A et al: Thyroid hormone is an MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 72: 180-187, 2007. (Pubitemid 46273502)
10. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY and Davis PJ: Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11(2): 183-190, 2008.
11. Rebbaa A, Chu F, Davis FB, Davis PJ and Mousa SA: Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 11(3): 269-276, 2008.
12. Cody V, Davis PJ and Davis FB: Molecular modeling of the thyroid hormone interactions with alphavbeta3 integrin. Steroids 72: 165-170, 2007. (Pubitemid 46273491)
13. Plow EF, Haas TA, Zhang L et al: Ligand binding to integrins. J Biol Chem 275: 21785-21788, 2000.
14. Masson-Gadais B, Houle F, Laferriere J et al: Integrin avb3, requirement for VEGFR2-mediated activation of SAPK2/p38 and Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 8: 37-52, 2003. (Pubitemid 36444089)
15. Sahni A and Francis CW: Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. Blood 104(12): 3635-3641, 2004.
16. Jeffery H, Davis SS and Ohagan DT: The preparation and characterization of poly (lactide-co-glycolide) microparticles. 1. Oil-in-water emulsion solvent evaporation. Int J Pharm 77(2-3): 169-175, 1991.
17. Song CX, Labhasetwar V, Qu X, Humphery WR, Shebuski RJ and Levi RJ: Formulation and characterization of biodegradable nanoparticles for intravascular local drug deliver. Journal of Controlled Release 43(2-3): 197-212, 1997. (Pubitemid 26390968)
18. Hermanson GT: Bio Conjugate Technique. San Diego, CA, Academic press, pp. 617-618, 1996.
19. Bergstrom K, Holmberg K, Safrani A, Hoffman AS, Edgell MJ, Kozlowski A, Hovanes BA and Harris JM: Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces. J Biomed Matter Res 26: 779-790, 1992.
20. Mousa SS and Mousa SA: Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J Cell Biochem 97(6): 1370-1378, 2006.
21. Parker A, Lohse C, Cheville J, Leibovich B, Igel T and Blute M: Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma. Int J Urol 4: 304-308, 2008.
22. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC and Nathanson KL: HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6): 435-446, 2008.
23. Clark PE and Cookson MS: The von Hippel-Lindau gene: turning discovery into therapy. Cancer 113(7 Suppl): 1768-1778, 2008.
24. Turcotte S, Sutphin PD and Giaccia AJ: Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death. Autophagy 4(7): 944-946, 2008.
25. Ji Q and Burk RD: Down-regulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation. Biochem Cell Biol 86(3): 227-234, 2008. (Pubitemid 351818098)
26. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE and Ueno NT: Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8: 975-985, 2007. (Pubitemid 47055391)
27. Lainakis' G and Bamias A: Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets 8(5): 349-358, 2008.
28. Theodossiou C, Skrepnik N, Robert EG, Prasad C, Axelrad TW, Schapira DV and Hunt JD: Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 86(8): 1596-1601, 1999. (Pubitemid 29489797)